COSM on Nasdaq

Cosmos Health Inc.

American wholesale-drugs company that raised $37.8 million in 2023 (SEC Form D)2

In its 2026 annual report the company says: “We operate in the healthcare sector and particularly in the Pharmaceutical and Nutraceutical businesses.”5 It is headquartered in Reno, United States.2 Its shares trade on Nasdaq under the symbol COSM.2

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with DataMeds AI, Inc., Cellyan Biotechnology Co., Ltd or Stemtech Corp, or pick any stock.

  • TickerCOSM on Nasdaq2
  • IndustryWholesale-Drugs, Proprietaries & Druggists' Sundries2
  • HeadquartersReno, United States2
  • Incorporated inNV3
  • Business address5 Agiou Georgiou, Pilea, Thessaloniki, J3 554383
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300NN5KFIEHPECJ852
  • StatusActive2
  • LEI statusIssued and current2
  • Registered address5725 Bravo Ave, 89506 Reno, United States2
  • Registered withBusiness Center (Secretary of State), E0386662009-62

See how the biggest companies compare on our leaderboards

Cosmos Health Inc. was incorporated in 2009 in Nevada and is a diversified, vertically integrated global healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of innovative medicines and repurposing drugs as well as operator of a telehealth platform.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

12.1%Gross margin6
-25.6%Operating margin6
-29.3%Net margin6
19.9%Revenue growth, 20256
-103.9%Return on equity6
0.20×Debt to equity6
-$8.5MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Wholesale brought in 91% of the revenue Cosmos Health Inc. broke down this way in fiscal 2025.

  1. Wholesale$59.3M691%up 15% from 2024
  2. Nutraceuticals and Pharmaceuticals$4.3M67%up 117% from 2024
  3. Pharma manufacturing$1.7M63%up 95% from 2024
  4. Other$1.2K60%
Business segments by year
Business segments20242025
Wholesale$51.6M$59.3M
Nutraceuticals and Pharmaceuticals$2.0M$4.3M
Pharma manufacturing$865.4K$1.7M
Other$0$1.2K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue88¢$57.4M
  • Research and development1¢$519.4K
  • Other costs8¢$5.5M
  • Interest3¢$1.9M

Out of $65.3M in revenue.6 The company lost money this year.

Financial statements

Revenue78910116$65.3M in 2025+65% since 2019
0$20.0M$40.0M$60.0M$80.0M2019: $39.7M$39.7M20192020: $55.4M$55.4M2020+40%2021: $56.2M$56.2M2021+2%2022: $50.3M$50.3M2022−10%2023: $53.4M$53.4M2023+6%2024: $54.4M$54.4M2024+2%2025: $65.3M$65.3M2025+20%
Gross profit78910116$7.9M in 2025+116% since 2019
0$2.5M$5.0M$7.5M$10.0M2019: $3.7M$3.7M20192020: $8.1M$8.1M2020+120%2021: $8.3M$8.3M2021+3%2022: $6.0M$6.0M2022−28%2023: $4.3M$4.3M2023−27%2024: $4.3M$4.3M2024−1%2025: $7.9M$7.9M2025+83%
Operating income78910116-$16.7M in 2025+6430% since 2019
-$30.0M-$20.0M-$10.0M0$10.0M2019: -$255.8K-$255.8K20192020: $2.7M$2.7M20202021: -$4.5M-$4.5M20212022: -$7.5M-$7.5M2022+65%2023: -$21.8M-$21.8M2023+192%2024: -$15.5M-$15.5M2024−29%2025: -$16.7M-$16.7M2025+7%
Net income78910116-$19.1M in 2025+480% since 2019
-$20.0M-$15.0M-$10.0M-$5.0M0$5.0M2019: -$3.3M-$3.3M20192020: $820.8K$820.8K20202021: -$8.0M-$8.0M20212022: -$13.8M-$13.8M2022+74%2023: -$18.5M-$18.5M2023+34%2024: -$16.2M-$16.2M2024−13%2025: -$19.1M-$19.1M2025+18%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
REVENUE$65.3M$54.4M
COST OF GOODS SOLD$57.4M$50.1M
GROSS PROFIT$7.9M$4.3M
General and administrative expenses$15.6M$11.7M
Salaries and wages$6.8M$5.7M
Sales and marketing expenses$150.2K$355.0K
Research and development costs$519.4K$533.3K
Impairment Charges$162.8K$292.0K
Depreciation and amortization expense$1.4M$1.2M
TOTAL OPERATING EXPENSES$24.6M$19.9M
LOSS FROM OPERATIONS-$16.7M-$15.5M
Other income (expense), net-$233.4K$86.7K
Interest expense-$1.9M-$1.0M
Interest income$396.4K$406.4K
Gain on equity investments, net$21.4K$2.5K
Gain on extinguishment of debt$68.6K$0
Non-cash interest expense-$722.8K$0
Change in fair value of derivative liability$1.5M$0
Unrealized loss on digital assets-$588.9K$0
Change in fair value of convertible notes-$1.3M$0
Foreign currency translation, net$339.8K-$121.5K
TOTAL OTHER INCOME (EXPENSE), NET-$2.4M-$638.2K
LOSS BEFORE INCOME TAXES-$19.1M-$16.2M
INCOME TAX EXPENSE$0$0
NET LOSS-$19.1M-$16.2M
Deemed dividend on issuance of warrants$0-$6.2M
Deemed dividend on warrant exchange/modification$0-$9.8K
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS-$19.1M-$22.4M
Foreign currency translation adjustment, net$2.5M-$1.7M
TOTAL COMPREHENSIVE LOSS-$16.7M-$24.1M
BASIC NET LOSS PER SHARE-$0.63-$1.17
DILUTED NET LOSS PER SHARE-$0.63-$1.17
Basic30.3M shares19.1M shares
Diluted30.3M shares19.1M shares

Compare Cosmos Health Inc. with another company

Corporate structure

Cosmos Health Inc. sits at the top of its group. 5 entities, 3 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Cosmos Health Inc.

  • Andreas Bovopoulos Filed SCHEDULE 13G/A on Cosmos Health Inc., latest Jun 5, 2026 (5 filings since Mar 6, 2025)
  • ARMISTICE CAPITAL, LLC Filed SCHEDULE 13G/A on Cosmos Health Inc., latest Aug 14, 2025 (5 filings since Feb 14, 2024)
  • Grigorios Siokas Filed SCHEDULE 13D/A on Cosmos Health Inc., latest May 27, 2025 (8 filings since Feb 11, 2022)
  • Athanasios Kolefas Filed SC 13D on Cosmos Health Inc., latest Nov 4, 2022
  • Hudson Bay Capital Management LP Filed SC 13G/A on Cosmos Health Inc., latest Feb 4, 2022
  • Cosmos Health Inc. Reno, Nevada, United States
    • Cosmofarm Ltd. Subsidiary · Greece
    • Decahedron Ltd. Subsidiary · United Kingdom
    • SkyPharm, S.A. Subsidiary · Greece
    • ZipDoctor Inc. Subsidiary · Texas, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Cosmos Health Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$12.7M6 Dec 31, 2025$11.0M6 Dec 31, 2024+15.8%
Accumulated depreciation$2.1M6 Dec 31, 2025$1.3M6 Dec 31, 2024+66.1%
Property and equipment, net$10.6M6 Dec 31, 2025$9.7M6 Dec 31, 2024+9.2%
Finance-lease assets$3.8K6 Dec 31, 2025$13.6K6 Dec 31, 2024−71.8%
Operating-lease assets (leased space)$596.8K6 Dec 31, 2025$696.2K6 Dec 31, 2024−14.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$715.7K6 Dec 31, 2025$315.1K6 Dec 31, 2024+127.1%
Marketable securities, current$46.2K6 Dec 31, 2025$21.1K6 Dec 31, 2024+118.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$49.7K6 Dec 31, 2025$49.7K6 Dec 31, 20240%
Intangible assets, net (excluding goodwill)$7.5M6 Dec 31, 2025$7.7M6 Dec 31, 2024−2.4%
Finite-lived intangibles, net$7.2M6 Dec 31, 2025$7.4M11 Dec 31, 2024−2.5%

Inventory

ItemLatestA year beforeChange
Inventory, total$5.8M6 Dec 31, 2025$4.4M6 Dec 31, 2024+32.7%

Properties, in its own words

The Company rents and owns the following corporate offices and facilities:

· · The U.S. corporate office is located at 141 W. Jackson Blvd, Suite 4236, Chicago, Illinois 60604. The initial lease commenced in 2015 and has been amended several times since inception. The most recent amendment was executed on March 17, 2025 and extends the lease term through October 31, 2028. The monthly rent is $1,280.

The rest of Item 2

· · Our Greece office, as well as the office of SkyPharm S.A., is located at 5 Agiou Georgiou Street, 55438, Pilea, Thessaloniki, Greece. The Company entered into a new three-year lease commencing on October 1, 2024, at a monthly rate of €2,202 ($2,383).

· · The offices of Decahedron are located at Unit 14, Spice Green Centre, Flex Meadow, Harlow, CM19 5TR, Essex, United Kingdom. The lease commenced on September 25, 2020, at a monthly rate of £3,500 ($4,473).

· · CANA S.A. previously leased corporate office space located at Konstantinoupoleos 19, 14122, Irakleio, Athens, Greece. In late 2025, the company relocated its administrative offices to its wholly owned facility located at Irakleiou Street 443, Neo Irakleio, Athens, Greece, and no longer leases the Konstantinoupoleos premises. The owned facility includes approximately 54,000 square feet of production and administrative space and is licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA) for the manufacture of pharmaceuticals, food supplements, cosmetics, biocides, and medical devices.

· · The offices of Cosmofarm are located at Gonata Stylianou 15, Peristeri, Attiki, Greece 12133. The Company purchased this building on April 24, 2023 for a total cash consideration of $1,054,872.

Each of the above facilities is adequate for the Company’s current needs.

Item 2 of the 10-K filed Apr 15, 2026.5

Leadership

Who has led Cosmos Health Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Panagiotis Drakopoulos2011–2013
  2. Dimitrios Goulielmos2013–2015
  3. Grigorios Siokas2016–now

Chief financial officer

  1. Vasileios Mavrogiannis2011–2012
  2. Grigorios Siokas2016
  3. Georgios Terzis2020–now

Chief operating officer

  1. Pavlos Ignatiades2020
  2. Nikolaos Bardakis2023–now
201520202025
Board members and other officers (14)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Cosmofarm Ltd. Greece4
  • Decahedron Ltd. United Kingdom4
  • SkyPharm, S.A. Greece4
  • ZipDoctor Inc. Texas4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Cosmos Holdings Inc.Oct 31, 2013 to Dec 19, 20223
  • PRIME ESTATES & DEVELOPMENTS INCOct 20, 2009 to Jan 3, 20143

Timeline

  1. Oct 9, 20268-K Results of operations30
  2. Aug 20, 20268-K Results of operations31
  3. Jul 16, 20268-K Change to shareholders' rights; Executive or director change; Bylaws or fiscal year changed32
  4. Jul 6, 20268-K Regulation FD disclosure; Other events33
  5. May 22, 20268-K Results of operations34
  6. Apr 16, 20268-K Results of operations35
  7. Dec 18, 20258-K Listing notice or transfer36
  8. Nov 17, 20258-K Results of operations; Regulation FD disclosure37
  9. Oct 17, 20258-K Regulation FD disclosure; Other events38
  10. Oct 6, 20258-K Executive or director change39
  11. Oct 1, 20258-K Executive or director change; Bylaws or fiscal year changed; Shareholder vote40
  12. Sep 29, 20258-K Regulation FD disclosure41
  13. Aug 12, 2016New chief executive Grigorios Siokas becomes CEO14
  14. Oct 4, 2013New chief executive Dimitrios Goulielmos becomes CEO15
  15. Jun 23, 2011New chief executive Panagiotis Drakopoulos becomes CEO16
  16. Jul 21, 2009Founded Cosmos Health Inc. is founded2

Calendar

Coming up

  1. Nov 13, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.17) a share, on Nov 14, 2025.42

When it reported results

  1. Oct 9, 2026Reported quarterly or annual results30
  2. Aug 20, 2026Reported quarterly or annual results31
  3. May 22, 2026Reported quarterly or annual results34
  4. Apr 16, 2026Reported quarterly or annual results35
  5. Nov 17, 2025Reported quarterly or annual results37
  6. Nov 22, 2023Reported quarterly or annual results43
  7. Aug 15, 2023Reported quarterly or annual results44
  8. Apr 18, 2023Reported quarterly or annual results45

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

337 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 69 major events, 97 insider forms, 20 large holders, 3 private raises, 127 other. The latest 20:

  1. Oct 9, 20268-K EDGAR
  2. Aug 20, 20268-K EDGAR
  3. Aug 18, 202610-Q EDGAR
  4. Aug 14, 2026NT 10-Q EDGAR
  5. Jul 31, 20264 EDGAR
  6. Jul 30, 20264 EDGAR
  7. Jul 30, 20264 EDGAR
  8. Jul 22, 2026RW EDGAR
  9. Jul 17, 2026S-8 EDGAR
  10. Jul 16, 20268-K EDGAR
  11. Jul 6, 20268-K EDGAR
  12. Jun 17, 20264 EDGAR
  13. Jun 12, 20264 EDGAR
  14. Jun 12, 20264 EDGAR
  15. Jun 11, 20264 EDGAR
  16. Jun 11, 20264 EDGAR
  17. Jun 11, 20264 EDGAR
  18. Jun 11, 20264 EDGAR
  19. Jun 11, 20264 EDGAR
  20. Jun 11, 20264 EDGAR

The 337 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

58 open-market trades by officers, directors and large owners since October 2021: 56 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jul 30, 2026Siokas GrigoriosChief Executive OfficerBuy349,825$0.20$70.0KForm 4
Jul 29, 2026Siokas GrigoriosChief Executive OfficerBuy766,284$0.18$137.9KForm 4
Jun 16, 2026Terzis GeorgiosChief Financial OfficerBuy168,135$0.25$42.0KForm 4
Jun 11, 2026Siokas GrigoriosChief Executive OfficerBuy218,447$0.21$45.9KForm 4
Jun 10, 2026Siokas GrigoriosChief Executive OfficerBuy701,447$0.23$161.3KForm 4
Feb 12, 2026Siokas GrigoriosChief Executive OfficerBuy388,532$0.37$143.8KForm 4
Feb 11, 2026Siokas GrigoriosChief Executive OfficerBuy291,262$0.41$119.4KForm 4
Jan 23, 2026Siokas GrigoriosChief Executive OfficerBuy90,325$0.50$45.2KForm 4
Jan 20, 2026Siokas GrigoriosChief Executive OfficerBuy353,321$0.50$176.7KForm 4
Jan 14, 2026Siokas GrigoriosChief Executive OfficerBuy493,495$0.45$222.1KForm 4
Jan 12, 2026Siokas GrigoriosChief Executive OfficerBuy113,185$0.50$56.6KForm 4
Jan 8, 2026Siokas GrigoriosChief Executive OfficerBuy156,190$0.52$81.2KForm 4
Jan 7, 2026Siokas GrigoriosChief Executive OfficerBuy124,880$0.52$64.9KForm 4
Jan 6, 2026Siokas GrigoriosChief Executive OfficerBuy133,953$0.54$72.3KForm 4
Dec 19, 2025Siokas GrigoriosChief Executive OfficerBuy88,314$0.49$43.3KForm 4
Dec 15, 2025Siokas GrigoriosChief Executive OfficerBuy168,472$0.42$70.8KForm 4
Nov 28, 2025Siokas GrigoriosChief Executive OfficerBuy76,360$0.64$48.9KForm 4
Nov 25, 2025Siokas GrigoriosChief Executive OfficerBuy55,732$0.63$35.1KForm 4
Nov 21, 2025Siokas GrigoriosChief Executive OfficerBuy56,080$0.68$38.1KForm 4
Nov 20, 2025Siokas GrigoriosChief Executive OfficerBuy51,315$0.62$31.8KForm 4

All 58 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 21, 2023Raised $5.2 million in a private offering of equity Form D: 3 investors so far Form D
  2. Dec 21, 2022Raised $32.5 million in a private offering of equity Form D: named in the filing: Anastasios Aslidis, Demetrios G. Demetriades, Grigorios Siokas, Manfred J. Ziegler, John J. Hoidas Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
UBS Group AG594,462$110.0K0.0%+581,728
Vanguard Fiduciary Trust Co333,842$61.8K0.0%+238,107
Jane Street Group, LLC289,287$53.4K0.0%New
Geode Capital Management, LLC282,094$52.1K0.0%−36,017
BlackRock, Inc.267,797$49.5K0.0%No change
Vanguard Capital Management LLC173,966$32.2K0.0%+33,959
Northern Trust Corp53,887$10.0K0.0%+33,333
State Street Corp45,243$8.4K0.0%No change
Sassicaia Capital Advisers LLC36,000$6.6K0.0%New
Kestra Private Wealth Services, LLC13,000$2.4K0.0%New
Simplex Trading, LLC7,138$1.3K0.0%+3,335
National Bank Of Canada /fi/6,357$1.1K0.0%No change
Group One Trading LLC1,700$3140.0%−673
Allworth Financial LP1,241$2300.0%No change
Tower Research Capital LLC (TRC)753$1390.0%−2
SBI Securities Co., Ltd.299$550.0%+187
Citigroup Inc43$80.0%−947
Wells Fargo & Company/mn40$70.0%No change
Valley National Advisers Inc1$10.0%New
Barclays PLC1$00.0%New
Fmr LLC0$00.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Cosmos Health Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARCosmos Health Inc.1
  • CIK0001474167
  • Employer ID (EIN)27-06117585
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
  • Incorporated inNevada5
  • Fiscal year endsDecember 311
  • Industry code (SIC)5122 Wholesale-Drugs, Proprietaries & Druggists' Sundries1
  • SEC reviewing officeOffice of Trade & Services, Division of Corporation Finance1
  • Business address5 Agiou Georgiou, Pilea, Thessaloniki, J3 554381
  • Phone312-536-31021
  • Shares outstanding100,633,773 as of Aug 18, 202613
  • Public float$9.5M as of Jun 30, 20255
  • AuditorRBSM LLP, New York, NY PCAOB ID 587; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceOct 20, 20091
  • Filings632 in all: 8-K (144), 4 (126), 10-Q (49), CORRESP (28), UPLOAD (28), NT 10-Q (21), S-1/A (19), 424B3 (18)1
    All 45 form types

    10-K (17), 5 (17), EFFECT (15), NT 10-K (15), 3 (14), 8-K/A (14), SC 13G/A (9), S-1 (7), SCHEDULE 13G/A (7), POS AM (6), S-3 (6), S-3/A (6), D (5), DEF 14A (5), PRE 14A (5), PRE 14C (5), SC 13D (5), 10-K/A (4), DEF 14C (4), 4/A (3), 424B5 (3), DEFA14A (3), S-11/A (3), SC 13D/A (3), SC 13G (3), SCHEDULE 13D/A (3), RW (2), 5/A (1), 8-A12B (1), 8-A12G (1), CERT (1), D/A (1), PRER14A (1), PRER14C (1), S-1MEF (1), S-8 (1), SCHEDULE 13G (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2026
    Quarterly report (10-Q) Aug 18, 2026
    Proxy statement (DEF 14A) Jun 2, 2026
    Latest 8-K (8-K) Oct 9, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001COSMNasdaq

From the cover page of the 10-K filed Apr 15, 2026 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks Cosmos Health Inc. names in Item 1A of its 10-K filed Apr 15, 2026: 1 risk under these headings, as written.5

  • Most-Favoured-Nation (MFN) Pricing and Section 232 Tariffs

Legal proceedings

We are aware of certain legal proceedings, which are disclosed in Note 15 – Commitments and Contingencies to the financial statements. Other than the matters described therein, we are not aware of any pending legal proceedings to which any of our officers, directors, or beneficial holders of 5% or more of our voting securities are adverse to us or have a material interest adverse to us.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50